Drug intelligence / Profile preview

IN-C005

Development stage: Phase 1
Lead developer: HK inno.N Corporation
Modality: Small Molecules
Administration: Oral

Overview

IN-C005 is an incrementally modified drug (IMD) under development by HK inno.N for the treatment of gastroesophageal reflux disease (GERD) and Helicobacter pylori infections. It is administered orally. The precise mechanism of action has not been disclosed publicly as of April 2025. Clinical trials have evaluated its pharmacokinetics, pharmacodynamics, and safety/tolerability in healthy subjects[1][2][4][5][7].

Other names: tegoprazan/sodium bicarbonate fixed-dose combination

Targets

HCl (Hydrochloric acid)ATP4A (Potassium-transporting ATPase subunit alpha gastric)

Beyond the preview

Go deeper on IN-C005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-C005.

Explore the full profile